Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be built on Long Island.

JonesTrading analyst Soumit Roy has assigned their bullish stance on EDIT stock, giving a Buy rating today. Soumit Roy’s rating is based ...

The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Editas Medicine (Nasdaq: EDIT) has announced plans to seek a partner or buyer for its lead CRISPR program, reni-cel, as the ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for ...

Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the FDA, a groundbreaking treatment which restores vision to children and adults with a rare inherited ...